PT  - JOURNAL ARTICLE
AU  - Myall, Ashleigh
AU  - Peach, Robert L.
AU  - Wan, Yu
AU  - Mookerjee, Siddharth
AU  - Jauneikaite, Elita
AU  - Bolt, Frankie
AU  - Price, James
AU  - Davies, Frances
AU  - Weiße, Andrea Y.
AU  - Holmes, Alison
AU  - Barahona, Mauricio
TI  - Characterising contact in disease outbreaks via a network model of spatial-temporal proximity
AID  - 10.1101/2021.04.07.21254497
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.04.07.21254497
4099  - http://medrxiv.org/content/early/2021/04/09/2021.04.07.21254497.short
4100  - http://medrxiv.org/content/early/2021/04/09/2021.04.07.21254497.full
AB  - Contact tracing is a key tool in epidemiology to identify and control outbreaks of infectious diseases. Existing contact tracing methodologies produce contact maps of individuals based on a binary definition of contact which can be hampered by missing data and indirect contacts. Here, we present a Spatial-temporal Epidemiological Proximity (StEP) model to recover contact maps in disease outbreaks based on movement data. The StEP model accounts for imperfect data by considering probabilistic contacts between individuals based on spatial-temporal proximity of their movement trajectories, creating a robust movement network despite possible missing data and unseen transmission routes. Using real-world data we showcase the potential of StEP for contact tracing with outbreaks of multidrug-resistant bacteria and COVID-19 in a large hospital group in London, UK. In addition to the core structure of contacts that can be recovered using traditional methods of contact tracing, the StEP model reveals missing contacts that connect seemingly separate outbreaks. Comparison with genomic data further confirmed that these recovered contacts indeed improve characterisation of disease transmission and so highlights how the StEP framework can inform effective strategies of infection control and prevention.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAM was supported in part by a scholarship from the Medical Research Foundation National PhD Training Programme in Antimicrobial Resistance Research (MRF-145-0004-TPG-AVISO), as well as by the National Institute for Health Research Academy. RP was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Project-ID 424778381-TRR 295. FD is supported by the Medical research council Clinical academic research partnership scheme. AH is a National Institute for Health Research Senior Investigator. AH is also partly funded by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Healthcare Associated Infections and Antimicrobial Infections in partnership with Public Health England, in collaboration with, Imperial Healthcare Partners, University of Cambridge and University of Warwick (NIHR grant code: NIHR200876). YW is fully funded by the same NIHR grant as AH. AM, RP, and MB acknowledge funding from EPSRC grant EP/N014529/1 to MB, supporting the EPSRC Centre for Mathematics of Precision Healthcare. EJ is a Rosetrees/Stoneygrate 2017 Imperial College Research Fellow, funded by Rosetrees Trust and the Stoneygate Trust (fellowship no. M683). The underlying investigation received financial support from the World Health Organization (WHO). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research, the Department of Health and Social Care or Public Health England or those of the WHO.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study ethics were granted and approved through Imperial College London NHS Trust service evaluations (Ref:386,379,473). All patient pathway data was collected from the central business intelligence system and fully pseudanonymised before analysis, in accordance with ethics 15_LO_0746."All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe patient pathway datasets generated and analysed specifically for the study are not publicly available to protect anonymity of included hospital patients. However, for datasets incorporated from existing studies, we refer readers to \textit{Boonyasiri et al.}~\cite{IMP2021} for Case study 1 data on CPE\textsubscript{IMP}, and \textit{Price et al.}\cite{Price_Mookerjee2020} for Case study 3 data on hospital acquired COVID-19. https://github.com/ashm97/StEP